<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | George Tolstrup | Activity</title>
	<link>https://www.catswannabecats.com/members/teambuffer06/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/teambuffer06/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for George Tolstrup.</description>
	<lastBuildDate>Mon, 22 Jun 2026 07:41:20 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">6de5d7e5b85429b411b37cbdadb4ddc5</guid>
				<title>George Tolstrup posted an update: Major depressive disorders (MDDs) constitute a leading cause [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/25833/</link>
				<pubDate>Mon, 09 Jun 2025 11:53:53 -0400</pubDate>

									<content:encoded><![CDATA[<p>Major depressive disorders (MDDs) constitute a leading cause of disability worldwide and current pharmacological treatments are partially effective. The gut microbiota (GM) has recently emerged as a target of therapeutic interest for MDDs. In this study, we transfer GM from mice that sustained unpredictable chronic mild stress (UCMS) to healthy&hellip;<span class="activity-read-more" id="activity-read-more-25833"><a href="https://www.catswannabecats.com/activity/p/25833/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">63a06ee06c68e5658103bbf645e95dee</guid>
				<title>George Tolstrup posted an update: Accordingly, the effect of miR-206 mimics was attenuated by [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/24338/</link>
				<pubDate>Sun, 08 Jun 2025 12:19:06 -0400</pubDate>

									<content:encoded><![CDATA[<p>Accordingly, the effect of miR-206 mimics was attenuated by the overexpression of KLF4 in adipocytes. Taken together, we identified the expression profiles of miRNAs in adipocytes, which revealed that miR-206 acts as a suppressor of adipogenesis.Gas chromatography-mass spectrometry (GC-MS) analysis revealed that castasterone and its biosynthetic&hellip;<span class="activity-read-more" id="activity-read-more-24338"><a href="https://www.catswannabecats.com/activity/p/24338/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">bda7c609a9562e1a6c1b7e4e656e8bd2</guid>
				<title>George Tolstrup posted an update: We demonstrated that exogenous ketone supplementation [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/15169/</link>
				<pubDate>Mon, 02 Jun 2025 12:19:58 -0400</pubDate>

									<content:encoded><![CDATA[<p>We demonstrated that exogenous ketone supplementation improved motor performance to various degrees in rodent models, while effectively elevated R-βHB and in some cases offsets postexercise blood glucose elevations. Our results suggest that improvement of motor performance varies depending on the strain of rodents, specific ketone formulation,&hellip;<span class="activity-read-more" id="activity-read-more-15169"><a href="https://www.catswannabecats.com/activity/p/15169/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">bca7bfaa3490b79f2341fd422a6a900c</guid>
				<title>George Tolstrup posted an update: Introduction The rationale for intraperitoneal (IP) drug [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/6874/</link>
				<pubDate>Sat, 31 May 2025 17:25:22 -0400</pubDate>

									<content:encoded><![CDATA[<p>Introduction The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly vascularized PM. Despite a history of more than three decades, many aspects of IP drug delivery&hellip;<span class="activity-read-more" id="activity-read-more-6874"><a href="https://www.catswannabecats.com/activity/p/6874/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">81bd1ae3a4d04ef3cba0b7e1ad8f012c</guid>
				<title>George Tolstrup became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/6712/</link>
				<pubDate>Sat, 31 May 2025 17:03:49 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>